{"schema_version":"secwatch.filing_event.v1","accession":"0001285550-23-000019","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.224929+00:00","generated_at":"2026-06-18T17:12:05.208524+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ClearPoint Neuro reports Q4 2022 revenue $5.2M (+21% YoY); full-year revenue $20.6M (+26% YoY)","bullets":["Q4 2022 revenue $5.2M, up 21% YoY; full-year revenue $20.6M, up 26% YoY (record).","Biologics & drug delivery revenue $9.1M for 2022, up 34% YoY; over 50 partners.","Gross margin 66% for 2022 vs 68% in 2021; Q4 gross margin 64% vs 77%.","Cash & short-term investments $37.5M at Dec 31, 2022, down from $54.1M.","Reiterates 2023 revenue guidance $25-27M, expecting >20% growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001285550-23-000019","json":"https://secwatch.observer/filing/0001285550-23-000019.json","markdown":"https://secwatch.observer/filing/0001285550-23-000019.md","text":"https://secwatch.observer/filing/0001285550-23-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000128555023000019/0001285550-23-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000128555023000019/clpt-20230301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T17:12:05.208524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6b2ae64aa5eda6907b60c0ba9f48995310d1b394","claim":"ClearPoint Neuro, Inc. reported the year ended December 31, 2022 results: revenue $20.6 million. Guidance reaffirmed.","evidence_excerpt":"Total revenue was $20.6 million and $16.3 million for the years ended December 31, 2022 and 2021, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555023000019/0001285550-23-000019-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$20.6 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"bbd9ccd3476dd33f48c3b4f6646686d4ff1c6b93","claim":"ClearPoint Neuro, Inc. reported the three months ended December 31, 2022 results: revenue $5.2 million.","evidence_excerpt":"Total revenue was $5.2 million for the three months ended December 31, 2022, and $4.3 million for the three months ended December 31, 2021, which represents an increase of $0.9 million, or 21%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555023000019/0001285550-23-000019-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Revenue","value":"$5.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}